Patents by Inventor Francois Meyer

Francois Meyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
    Patent number: 7465451
    Abstract: The invention relates to a monoclonal antibody directed against the human interferon class I receptor (IFN-R) characterized by the following properties: it recognizes the extracellular domain of the human IFN-R, and it has a neutralizing capacity against the biological properties of the human type I-IFN. It further concerns their use for the diagnosis.
    Type: Grant
    Filed: December 27, 2006
    Date of Patent: December 16, 2008
    Assignee: Medarex, Inc.
    Inventors: Patrick Benoit, Francois Meyer, Deborah Maguire, Ivan Plavec, Michael Gerard Tovey
  • Monoclonal Antibodies Against The Interferon Receptor, With Neutralizing Activity Against Type I Interferon
    Publication number: 20080226647
    Abstract: The invention relates to a monoclonal antibody directed against the human interferon class I receptor (IFN-R) characterized by the following properties: it recognizes the extracellular domain of the human IFN-R, and it has a neutralizing capacity against the biological properties of the human type I-IFN. It further concerns their use for the diagnosis.
    Type: Application
    Filed: May 9, 2008
    Publication date: September 18, 2008
    Applicant: Medarex, Inc.
    Inventors: Patrick Benoit, Francois Meyer, Deborah Maguire, Ivan Plavec, Michael G. Tovey
  • MONOCLONAL ANTIBODIES AGAINST THE INTERFERON RECEPTOR, WITH NEUTRALIZING ACTIVITY AGAINST TYPE I INTERFERON
    Publication number: 20070128701
    Abstract: The invention relates to a monoclonal antibody directed against the human interferon class I receptor (IFN-R) characterized by the following properties: it recognizes the extracellular domain of the human IFN-R, and it has a neutralizing capacity against the biological properties of the human type I-IFN. It further concerns their use for the diagnosis.
    Type: Application
    Filed: December 27, 2006
    Publication date: June 7, 2007
    Applicant: Medarex, Inc.
    Inventors: Patrick Benoit, Francois Meyer, Deborah Maguire, Ivan Plavec, Michael Tovey
  • Monoclonal antibodies against the interferon receptor, with neutralizing activity against type 1 interferon
    Patent number: 7179465
    Abstract: The invention relates to a monoclonal antibody directed against the human interferon class I receptor (IFN-R) characterized by the following properties: it recognizes the extracellular domain of the human IFN-R, and it has a neutralizing capacity against the biological properties of the human type I-IFN. It further concerns their use for the diagnosis.
    Type: Grant
    Filed: April 14, 2004
    Date of Patent: February 20, 2007
    Assignee: Medarex, Inc.
    Inventors: Patrick Benoit, Francois Meyer, Deborah Maguire, Ivan Plavec, Michael G. Tovey
  • Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
    Publication number: 20040191840
    Abstract: The invention relates to a monoclonal antibody directed against the human interferon class I receptor (IFN-R) characterized by the following properties: it recognizes the extracellular domain of the human IFN-R, and it has a neutralizing capacity against the biological properties of the human type I-IFN. It further concerns their use for the diagnosis.
    Type: Application
    Filed: April 14, 2004
    Publication date: September 30, 2004
    Inventors: Patrick Benoit, Francois Meyer, Deborah Maguire, Ivan Plavec, Michael G. Tovey
  • Isolated peptide or polypeptide of the extracellular portion of the human interferon receptor (IFN-R).
    Patent number: 6787634
    Abstract: A monoclonal antibody is provided which is directed against the human interferon type I receptor (IFN-R), which recognizes the extracellular domain of the human IFN-R and which has neutralizing capacity against the biological properties of human type I-IFN. Diagnostic and therapeutic applications for the monoclonal antibody also are provided.
    Type: Grant
    Filed: February 2, 1999
    Date of Patent: September 7, 2004
    Assignee: Medisup International, N.V.
    Inventors: Patrick Benoit, Francois Meyer, Debborah Maguire, Ivan Plavec, Michael G. Tovey
  • Water-soluble polypeptides having a high affinity for &agr; and &bgr; interferons
    Patent number: 6475983
    Abstract: Water-soluble polypeptides having high affinity for interferons &agr; and &bgr;; DNA sequences and expression cells; a preparation method therefor; drugs; compositions containing same; and uses thereof as a diagnostic agent or for producing antibodies.
    Type: Grant
    Filed: February 17, 1993
    Date of Patent: November 5, 2002
    Assignee: Medisup International N.V.
    Inventors: Pierre Eid, Ion Gresser, Georges Lutfalla, Francois Meyer, Knud Erik Mogensen, Michael Tovey, Gilles Uze
  • Process for the preparation of protease inhibitors
    Publication number: 20020142414
    Abstract: The invention relates to DNA sequences which code an eglin, expression plasmids containing such DNA sequences, hosts transformed with such expression plasmids, novel eglin compounds produced from such transformed hosts, monoclonal antibodies against eglins, hybridoma cells which produce such antibodies, and test kits for immunoassays containing such antibodies, and furthermore the processes for their preparation and a process for the preparation of eglins with the aid of the transformed hosts. The eglins which can be prepared according to the invention have useful pharmacological properties.
    Type: Application
    Filed: January 22, 2001
    Publication date: October 3, 2002
    Applicant: UCP Gen-Pharma AG
    Inventors: Hans Rink, Manfred Liersch, Peter Sieber, Werner Rittel, Francois Meyer, Ursula Seemuller, Hans Fritz, Walter Marki, Sefik Alkan
  • MONOCLONAL ANTIBODIES AGAINST THE INTERFERON RECEPTOR, WITH NEUTRALIZING ACTIVITY AGAINST TYPE 1 INTERFERON
    Publication number: 20020055492
    Abstract: A monoclonal antibody is provided which is directed against the human interferon type I receptor (IFN-R), which recognizes the extracellular domain of the human IFN-R and which has neutralizing capacity against the biological properties of human type I-IFN. Diagnostic and therapeutic applications for the monoclonal antibody also are provided.
    Type: Application
    Filed: February 2, 1999
    Publication date: May 9, 2002
    Inventors: PATRICK BENOIT, FRANCOIS MEYER, DEBBORAH MAGUIRE, IVAN PLAVEC, MICHAEL G. TOVEY
  • Process for preparing recombinant eglin, protease inhibitor
    Patent number: 6342373
    Abstract: The invention relates to DNA sequences which code an eglin, expression plasmids containing such DNA sequences, hosts transformed with such expression plasmids, novel eglin compounds produced from such transformed hosts, monoclonal antibodies against eglins, hybridoma cells which produce such antibodies, and test kits for immunoassays containing such antibodies, and furthermore the processes for their preparation and a process for the preparation of eglins with the aid of the transformed hosts. The eglins which can be prepared according to the invention have useful pharmacological properties.
    Type: Grant
    Filed: May 24, 1991
    Date of Patent: January 29, 2002
    Assignee: UCP GEN-Pharma AG
    Inventors: Hans Rink, Manfred Liersch, Peter Sieber, Werner Rittel, Francois Meyer, Ursula Seemüller, Hans Fritz, Walter Märki, Sefik Alkan
  • Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
    Patent number: 5919453
    Abstract: A monoclonal antibody directed against the human interferon type I receptor (IFN-R), which recognizes the extracellular domain of the human IFN-R and has neutralizing capacity against the biological properties of human type I-IFN. Diagnostic applications for the monoclonal antibody also are provided.
    Type: Grant
    Filed: December 5, 1994
    Date of Patent: July 6, 1999
    Assignee: Laboratoire European De Biotechnologie S.A.
    Inventors: Patrick Benoit, Francois Meyer, Debborah Maguire, Ivan Plavec, Michael G. Tovey
  • Polypeptides and process for the production thereof
    Patent number: 5089400
    Abstract: Recombinant DNA molecules and hosts transformed with them are described which produce polypeptides displaying a human lymphoblastoid interferon activity. There are also provided processes for the preparation of said recombinant DNA molecules, said hosts, and said lymphoblastoid interferon-like polypeptides. The polypeptides of the invention are useful as immunomodulators, especially as antiviral, antitumor and anticancer agents.
    Type: Grant
    Filed: March 7, 1989
    Date of Patent: February 18, 1992
    Assignee: Ciba-Geigy Corporation
    Inventor: Francois Meyer
  • Hybrid interferons
    Patent number: 5071761
    Abstract: Novel hybrid interferons are produced which are derived from lymphoblastoid interferons .alpha.-2 and .alpha.-3 belonging to the interferon .alpha.B and .alpha.D groups, respectively. The novel hybrid interferons possess valuable antiviral and antiproliferative properties.
    Type: Grant
    Filed: July 18, 1989
    Date of Patent: December 10, 1991
    Assignee: Ciba-Geigy Corporation
    Inventors: Francois Meyer, Albert Hinnen, Andreas Meister, Markus G. Grutter, Sefik Alkan
  • Hybrid interferons
    Patent number: 4885166
    Abstract: Novel hybrid interferons are produced which are derived from lymphoblastoid interferons .alpha.-2 and .alpha.-3 belonging to the interferon .alpha.B and .alpha.D groups, respectively. The novel hybrid interferons possess valuable antiviral and antiproliferative properties.
    Type: Grant
    Filed: June 5, 1986
    Date of Patent: December 5, 1989
    Assignee: Ciba-Geigy Corporation
    Inventors: Francois Meyer, Albert Hinnen, Andreas Meister, Markus G. Grutter, Sefik Alkan